Self-Assessment Post-Test

Androgen-Independent Prostate Cancer

RIUPost-Test(Sanofi)_04-30.qxd 4/30/07 3:28 PM Page S41 SELF-ASSESSMENT POST-TEST Challenging the Current Treatment Paradigm of Androgen-Independent Prostate Cancer 1. Which of the following were trial findings related to treatment with atrasentan in hormone-refractory prostate cancer patients with asymptomatic progressive metastatic disease? a. Quality of life parameters were more favorable in patients on atrasentan. b. There was a delay in time to development of bone pain in the atrasentan patients. c. Both a and b 2. Which of the following actions can be taken with patients with prostate cancer who are being managed with androgen deprivation therapy and are discovered to have a rising PSA? a. Administer further antiandrogen therapy if maximum antiandrogen blockade has not been used. b. Withdraw antiandrogens for patients on maximum antiandrogen blockade. c. Initiate second-line hormonal therapies using less commonly used antiandrogens, corticosteroids, adrenal and testicular enzyme inhibitors, or estrogens. d. Any of the above actions are acceptable. 3. In the SWOG 9916 trial, docetaxel/estramustine was compared to mitoxantrone/prednisone with overall survival as the primary endpoint. Which combination demonstrated a 20% decrease in risk of death? a. docetaxel/estramustine b. mitoxantrone/prednisone 4. In the TAX 327 trial, 2 schedules of docetaxel/prednisone were compared against mitoxantrone/prednisone with the primary endpoint being overall survival. Which combination demonstrated a significantly decreased chance of dying? a. weekly dosing of docetaxel/prednisone b. weekly dosing of mitoxantrone/prednisone c. every 3 weeks dosing of docetaxel/prednisone 5. In the TAX 327 trial, both docetaxel/prednisone arms of the study were ________ to mitoxantrone/prednisone in palliation of bone pain. a. inferior to b. similar to c. superior to 6. Which of the following are considered endpoints for high-risk, localized prostate cancer? 1. development of secondary primary malignancies 2. clinical relapse 3. death from cancer 4. biochemical recurrence a. 1, 2, and 3 b. 2, 3, and 4 c. 1, 3, and 4 d. all of the above 7. In the study by Freedland and colleagues from Johns Hopkins, patients were found to be at high risk for death with a PSA doubling time of: a. less than 3 months b. 4 to 6 months c. 6 to 7 months d. 7 to 9 months 8. True or false? For the patient who is classified with high-risk, localized prostate cancer, monotherapy with either surgery or radiation therapy is considered adequate treatment. a. true b. false 9. Prognostic factors in prostate cancer include which of the following? a. palpable or image-identified evidence of extra-prostatic extension b. high biopsy Gleason scores (8-10) c. serum PSA levels of 20 ng/mL or higher d. all of the above 10. True or false? Neoadjuvant systemic chemotherapy has been shown to achieve complete pathological response in both prostate and breast cancer. a. true b. false VOL. 9 SUPPL. 2 2007 REVIEWS IN UROLOGY S41 RIUPost-Test(Sanofi)_04-30.qxd 4/30/07 3:28 PM Page S42 EVALUATION FORM Challenging the Current Treatment Paradigm of Androgen-Independent Prostate Cancer Project ID: 4465 ES 13 To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgment for completing this activity. Please answer the following questions by circling the appropriate rating: 5
Strongly Agree 4
Agree 3
Neutral 2
Disagree 1
Strongly Disagree EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES After completing this activity, I am now better able to: • Describe how to identify when patients with prostate cancer are developing androgen insensitivity • Explain the appropriate time to start treatment for androgen-independent prostate cancer • Identify treatment strategies for androgen-independent prostate cancer • List the limitations of curative interventions for high-risk, clinically localized prostate cancer • Describe the application of appropriate neoadjuvant and adjuvant treatments • Outline a paradigm for a multidisciplinary approach to treating advanced prostate cancer 5 5 5 5 5 5 4 4 4 4 4 4 3 3 3 3 3 3 2 2 2 2 2 2 1 1 1 1 1 1 5 5 5 5 5 5 4 4 4 4 4 4 3 3 3 3 3 3 2 2 2 2 2 2 1 1 1 1 1 1 OVERALL EFFECTIVENESS OF THE ACTIVITY The content presented: • Was timely and will influence how I practice • Enhanced my current knowledge base • Addressed my most pressing questions • Provided new ideas or information I expect to use • Addressed competencies identified by my specialty • Avoided commercial bias or influence IMPACT OF THE ACTIVITY Name one thing you intend to change in your practice as a result of completing this activity: Please list any topics you would like to see addressed in future educational activities: Additional comments about this activity: FOLLOW-UP As part of our continuous quality improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate if you would be willing to participate in such a survey: ❒ Yes, I would be interested in participating in a follow-up survey. ❒ No, I’m not interested in participating in a follow-up survey. POST-TEST ANSWER KEY 1___ 2___ 3___ 4___ 5___ 6___ 7___ 8___ 9___ 10___ Request for Credit Name Organization Address Telephone Fax Degree Specialty City, State, Zip E-Mail If you wish to receive acknowledgment for completing this activity, please complete the post-test by selecting the best answer to each question, complete this evaluation verification of participation, and FAX to: 303-790-4876. FOR PHYSICIANS ONLY I certify my actual time spent to complete this educational activity to be: ❒ I participated in the entire activity and claim 2.0 credits. ❒ I participated in only part of the activity and claim _____ credits. Signature S42 VOL. 9 SUPPL. 2 2007 Date REVIEWS IN UROLOGY